We are live on ! Find out more
SCM

Suvretta Capital Management Portfolio holdings

AUM $3.92B
1-Year Est. Return 86.67%
This Fund
S&P 500
This Quarter Est. Return
+13.45%
1 Year Est. Return
+86.67%
3 Year Est. Return
+295.96%
5 Year Est. Return
+364.48%
10 Year Est. Return
+2,073.65%
AUM
$3.13B
AUM Growth
+$403M
Cap. Flow
+$107M
Cap. Flow %
3.43%
Top 10 Hldgs %
44.51%
Holding
113
New
15
Increased
22
Reduced
19
Closed
15

Top Buys

Rank Stock Value
1
BNTC icon
Benitec Biopharma
BNTC
+$63.9M
2
SBUX icon
Starbucks
SBUX
+$47.2M
3
CRWD icon
CrowdStrike
CRWD
+$34.7M
4
COF icon
Capital One
COF
+$33.5M
5
BIOA
BioAge Labs
BIOA
+$29.2M

Top Sells

Rank Stock Value
1
INSM icon
Insmed
INSM
+$65.4M
2
ACLX
Arcellx
ACLX
+$55M
3
ELV icon
Elevance Health
ELV
+$49.5M
4
RARE icon
Ultragenyx Pharmaceutical
RARE
+$46.4M
5
SYY icon
Sysco
SYY
+$37.2M

Sector Composition

Rank Sector Weight
1 Healthcare 53.04%
2 Technology 9.98%
3 Consumer Discretionary 7.64%
4 Communication Services 6.42%
5 Financials 4.7%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AVTR icon
76
Avantor
AVTR
$9.19B
$1.86M 0.06%
71,850
– –
IQV icon
77
IQVIA
IQV
$39.3B
$1.7M 0.05%
7,175
– –
SYK icon
78
Stryker
SYK
$130B
$1.58M 0.05%
4,360
– –
MDT icon
79
Medtronic
MDT
$112B
$1.57M 0.05%
17,460
– –
LKFT
80
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.77B
$1.36M 0.04%
47,200
– –
HCA icon
81
HCA Healthcare
HCA
$89.5B
$1.3M 0.04%
3,190
– –
NTRA icon
82
Natera
NTRA
$46.4B
$1.28M 0.04%
10,100
– –
ILMN icon
83
Illumina
ILMN
$28.4B
$1.14M 0.04%
8,730
– –
WAT icon
84
Waters Corp
WAT
$39.9B
$1.13M 0.04%
3,150
– –
CNTA
85
DELISTED
Centessa Pharmaceuticals
CNTA
$1.12M 0.04%
+70,000
New +$858K
CVS icon
86
CVS Health
CVS
$122B
$1.08M 0.03%
17,170
– –
MCK icon
87
McKesson
MCK
$101B
$905K 0.03%
1,830
– –
PACS icon
88
PACS Group
PACS
$7.67B
$799K 0.03%
+20,000
New +$727K
A icon
89
Agilent Technologies
A
$41.2B
$741K 0.02%
4,990
– –
EW icon
90
Edwards Lifesciences
EW
$51.7B
$732K 0.02%
11,100
– –
VLTO icon
91
Veralto
VLTO
$24B
$612K 0.02%
5,475
– –
RMD icon
92
ResMed
RMD
$30.7B
$583K 0.02%
2,390
– –
IONS icon
93
Ionis Pharmaceuticals
IONS
$9.4B
$433K 0.01%
10,800
– –
STE icon
94
Steris
STE
$23.1B
$371K 0.01%
1,530
– –
ZBH icon
95
Zimmer Biomet
ZBH
$18.4B
$352K 0.01%
3,260
– –
BAX icon
96
Baxter International
BAX
$14.2B
$303K 0.01%
7,970
– –
ALGN icon
97
Align Technology
ALGN
$12.3B
$280K 0.01%
1,100
– –
TECH icon
98
Bio-Techne
TECH
$11.3B
$208K 0.01%
+2,600
New +$195K
CI icon
99
Cigna
CI
$74.6B
– –
-4,800
Closed -$1.59M
CMG icon
100
Chipotle Mexican Grill
CMG
$41.5B
– –
-398,500
Closed -$25M
1 2 3
4
5

Similar funds

MIM
Meridiem Investment Management London, United Kingdom $3.92B AUM 1.64% 1-Year Est. Return
BCP
BSN Capital Partners London, United Kingdom $3.93B AUM 13.09% 1-Year Est. Return
AS
American Securities New York $3.93B AUM 52.22% 1-Year Est. Return
MSI
Mitsui Sumitomo Insurance Tokyo, Japan $3.9B AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
LWCA
Locust Wood Capital Advisers New York $3.95B AUM 33.1% 1-Year Est. Return
TFM
Trian Fund Management New York $3.86B AUM 26.59% 1-Year Est. Return
USCWA
U.S. Capital Wealth Advisors Austin, Texas $3.98B AUM 22.36% 1-Year Est. Return

Suvretta Capital Management's Q3 2024 Portfolio in Review

As of Q3 2024, Suvretta Capital Management held 113 positions worth $3.13B, up 15% from $2.72B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Suvretta Capital Management deployed $107M of net new capital in Q3 2024, opening 15 new positions and adding to 22 existing holdings. Its largest new stake was Starbucks: 550,309 shares worth $53.6M.

By sector, the portfolio is most concentrated in Healthcare at 53% of assets, down from 59% a quarter earlier, followed by Technology and Consumer Discretionary.

On the sell side, the largest reduction was Insmed, an estimated $65.4M trimmed.

  • Suvretta Capital Management's largest Q3 2024 buy was Starbucks: 550,309 shares worth $53.6M.
  • Suvretta Capital Management added most to Benitec Biopharma in Q3 2024, an estimated $63.9M increase.
  • Suvretta Capital Management's biggest Q3 2024 reduction was Insmed, cutting an estimated $65.4M.
  • Suvretta Capital Management fully exited Elevance Health in Q3 2024, selling an estimated $49.5M.
  • Suvretta Capital Management's ten largest holdings make up 45% of its $3.13B portfolio in Q3 2024.
  • Suvretta Capital Management opened 15 new positions and closed 15 in Q3 2024.
  • Suvretta Capital Management's portfolio value rose 15% quarter-over-quarter to $3.13B.

Based on Suvretta Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.